| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Lormetazepam | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | | Lormetazepam | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | | | Lormetazepam | hsa00500 | Starch and sucrose metabolism | 1.25E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Lormetazepam | hsa00730 | Thiamine metabolism | 2.32E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Lormetazepam | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | | Lormetazepam | hsa01523 | Antifolate resistance | 1.43E-03 | 2 | Q92820, P04818 | GGH, TYMS | More | | | Lormetazepam | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | | Lormetazepam | hsa03008 | Ribosome biogenesis in eukaryotes | 4.94E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | | | Lormetazepam | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | | | Lormetazepam | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | | | Lormetazepam | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Lormetazepam | hsa03030 | DNA replication | 5.00E-02 | 1 | P27694 | RPA1 | More | | | Lormetazepam | hsa03050 | Proteasome | 1.40E-02 | 1 | P55036 | PSMD4 | More | | | Lormetazepam | hsa04024 | cAMP signaling pathway | 3.37E-02 | 3 | P63092, P26678, P61586 | GNAS, PLN, RHOA | More | | | Lormetazepam | hsa04064 | NF-kappa B signaling pathway | 5.05E-04 | 11 | P10415, O00463, P01375, Q04759, Q9UDY8, Q13077, Q16548, Q8WV28, Q13315, P24522, P09341 | BCL2, TRAF5, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, BLNK, ATM, GADD45A, CXCL1 | More | | | Lormetazepam | hsa04071 | Sphingolipid signaling pathway | 8.39E-04 | 8 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2 | More | | | Lormetazepam | hsa04072 | Phospholipase D signaling pathway | 2.75E-02 | 3 | P61586, O14986, P63092 | RHOA, PIP5K1B, GNAS | More | | | Lormetazepam | hsa04080 | Neuroactive ligand-receptor interaction | 9.01E-04 | 10 | P08311, Q15722, P21453, Q9H228, O00398, P21462, P21730, Q16581, P07550, P35318 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, C3AR1, ADRB2, ADM | More | | | Lormetazepam | hsa04110 | Cell cycle | 1.97E-05 | 7 | P06493, O60566, O75293, P30304, P33981, P42773, P01106 | CDK1, BUB1B, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | | Lormetazepam | hsa04120 | Ubiquitin mediated proteolysis | 1.06E-04 | 6 | Q14145, Q13042, Q13191, P62837, Q15751, Q7Z6Z7 | KEAP1, CDC16, CBLB, UBE2D2, HERC1, HUWE1 | More | | | Lormetazepam | hsa04137 | Mitophagy - animal | 2.52E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | | | Lormetazepam | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | | | Lormetazepam | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | | | Lormetazepam | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | | | Lormetazepam | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | | | Lormetazepam | hsa04217 | Necroptosis | 4.24E-05 | 10 | P01375, P48023, Q14765, P07900, P15104, P05141, P01584, P0C0S5, Q99878, Q13557 | TNF, FASLG, STAT4, HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CAMK2D | More | | | Lormetazepam | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | | Lormetazepam | hsa04310 | Wnt signaling pathway | 4.17E-03 | 3 | P61586, P19784, P67870 | RHOA, CSNK2A2, CSNK2B | More | | | Lormetazepam | hsa04340 | Hedgehog signaling pathway | 1.05E-03 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | | Lormetazepam | hsa04510 | Focal adhesion | 4.07E-02 | 3 | O14986, P61586, Q16363 | PIP5K1B, RHOA, LAMA4 | More | | | Lormetazepam | hsa04514 | Cell adhesion molecules | 1.22E-02 | 2 | P23229, P30511 | ITGA6, HLA-F | More | | | Lormetazepam | hsa04520 | Adherens junction | 1.38E-04 | 3 | P19784, P67870, P61586 | CSNK2A2, CSNK2B, RHOA | More | | | Lormetazepam | hsa04612 | Antigen processing and presentation | 4.48E-02 | 5 | P13765, P26715, P26717, Q13241, P01732 | HLA-DOB, KLRC1, KLRC2, KLRD1, CD8A | More | | | Lormetazepam | hsa04613 | Neutrophil extracellular trap formation | 4.72E-04 | 15 | O60603, P05164, P08246, Q9UM07, P04908, Q93077, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, H2AC4; H2AC8, HIST1H2AC, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | | Lormetazepam | hsa04621 | NOD-like receptor signaling pathway | 5.21E-03 | 12 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, P01375, P09341, P59665, P59666, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, TNF, CXCL1, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | | Lormetazepam | hsa04640 | Hematopoietic cell lineage | 4.71E-03 | 5 | P21926, P07766, P01730, P06127, P09564 | CD9, CD3E, CD4, CD5, CD7 | More | | | Lormetazepam | hsa04650 | Natural killer cell mediated cytotoxicity | 3.67E-03 | 9 | P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | | Lormetazepam | hsa04657 | IL-17 signaling pathway | 1.35E-03 | 9 | P07900, O00463, Q16539, P49841, P09341, P14780, P80188, P01375, P01584 | HSP90AA1, TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF, IL1B | More | | | Lormetazepam | hsa04658 | Th1 and Th2 cell differentiation | 4.96E-07 | 10 | Q04759, P20963, P09693, Q16539, P06239, Q14765, P42226, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, LCK, STAT4, STAT6, GATA3, TBX21, HLA-DOB | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | | P06737 | PYGL | Glycogen phosphorylase, liver form | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.728 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 | | P06737 | PYGL | Glycogen phosphorylase, liver form | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.723 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.744 | | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | | P06737 | PYGL | Glycogen phosphorylase, liver form | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.736 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.742 | | P06737 | PYGL | Glycogen phosphorylase, liver form | P42226 | STAT6 | Signal transducer and activator of transcription 6 | 0.852 | | P06737 | PYGL | Glycogen phosphorylase, liver form | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.753 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.85 | | P06737 | PYGL | Glycogen phosphorylase, liver form | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.738 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.73 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.735 | | P06737 | PYGL | Glycogen phosphorylase, liver form | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.845 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.795 |
| | Lormetazepam | hsa04659 | Th17 cell differentiation | 6.05E-05 | 10 | Q04759, Q16539, P06239, P42226, P13765, P14778, Q9UL17, P23771, P09693, P20963 | PRKCQ, MAPK14, LCK, STAT6, HLA-DOB, IL1R1, TBX21, GATA3, CD3G, CD247 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | | P06737 | PYGL | Glycogen phosphorylase, liver form | P42226 | STAT6 | Signal transducer and activator of transcription 6 | 0.852 | | P06737 | PYGL | Glycogen phosphorylase, liver form | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.845 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.795 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.909 | | P06737 | PYGL | Glycogen phosphorylase, liver form | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.738 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.73 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.735 | | P06737 | PYGL | Glycogen phosphorylase, liver form | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.753 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.85 | | P06737 | PYGL | Glycogen phosphorylase, liver form | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.723 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.744 | | P06737 | PYGL | Glycogen phosphorylase, liver form | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.728 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 |
| | Lormetazepam | hsa04660 | T cell receptor signaling pathway | 3.75E-04 | 11 | P01375, Q9UDY8, Q04759, P10747, O95267, Q08881, P20963, P09693, P01732, Q16539, P49841 | TNF, MALT1, PRKCQ, CD28, RASGRP1, ITK, CD247, CD3G, CD8A, MAPK14, GSK3B | More | | | Lormetazepam | hsa04713 | Circadian entrainment | 4.94E-02 | 2 | P62873, P63092 | GNB1, GNAS | More | | | Lormetazepam | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Lormetazepam | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Lormetazepam | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | | | Lormetazepam | hsa04724 | Glutamatergic synapse | 3.65E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | | | Lormetazepam | hsa04726 | Serotonergic synapse | 2.52E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | | | Lormetazepam | hsa04730 | Long-term depression | 5.00E-02 | 1 | Q14344 | GNA13 | More | | | Lormetazepam | hsa04810 | Regulation of actin cytoskeleton | 2.68E-02 | 2 | P23229, Q14344 | ITGA6, GNA13 | More | | | Lormetazepam | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | | | Lormetazepam | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | | Lormetazepam | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.23E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | | | Lormetazepam | hsa04932 | Non-alcoholic fatty liver disease | 6.73E-05 | 9 | P01375, P49841, P18848, P48023, P01584, P13073, O15239, Q16718, O14521 | TNF, GSK3B, ATF4, FASLG, IL1B, COX4I1, NDUFA1, NDUFA5, SDHD | More | | | Lormetazepam | hsa04940 | Type I diabetes mellitus | 6.87E-04 | 2 | P48023, P01375 | FASLG, TNF | More | | | Lormetazepam | hsa04972 | Pancreatic secretion | 3.65E-02 | 2 | P63092, P61586 | GNAS, RHOA | More | | | Lormetazepam | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | | Lormetazepam | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | | | Lormetazepam | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | | | Lormetazepam | hsa05020 | Prion disease | 3.73E-04 | 11 | P13591, P01584, P11142, O15239, Q16718, O14521, P13073, P18848, P05141, P49841, Q16539 | NCAM1, IL1B, HSPA8, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, SLC25A5, GSK3B, MAPK14 | More | | | Lormetazepam | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.47E-03 | 12 | P49841, O15239, Q16718, O14521, P13073, P18848, Q13561, P05141, Q16539, P01584, Q08752, Q13557 | GSK3B, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, DCTN2, SLC25A5, MAPK14, IL1B, PPID, CAMK2D | More | | | Lormetazepam | hsa05032 | Morphine addiction | 9.04E-05 | 5 | P62873, P48169, P78334, P63092, P32298 | GNB1, GABRA4, GABRE, GNAS, GRK4 | More | | | Lormetazepam | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | | | Lormetazepam | hsa05142 | Chagas disease | 2.26E-02 | 3 | P01375, P30679, P48023 | TNF, GNA15, FASLG | More | | | Lormetazepam | hsa05143 | African trypanosomiasis | 1.51E-03 | 2 | P01375, P48023 | TNF, FASLG | More | | | Lormetazepam | hsa05144 | Malaria | 1.44E-02 | 4 | P60033, O60603, P35443, P26718 | CD81, TLR2, THBS4, KLRK1 | More | | | Lormetazepam | hsa05150 | Staphylococcus aureus infection | 3.62E-03 | 8 | P21730, P21462, O75015, P13765, Q16581, P59665, P59666, P12838 | C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | | Lormetazepam | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Lormetazepam | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | | | Lormetazepam | hsa05163 | Human cytomegalovirus infection | 1.49E-03 | 6 | P30511, P62873, Q14344, P61586, P63092, P61769 | HLA-F, GNB1, GNA13, RHOA, GNAS, B2M | More | | | Lormetazepam | hsa05169 | Epstein-Barr virus infection | 5.92E-03 | 12 | P13765, Q13547, O00463, P16070, P10415, Q16539, P24522, Q8WV28, P01375, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, CD44, BCL2, MAPK14, GADD45A, BLNK, TNF, TLR2, CD3G, CD247 | More | | | Lormetazepam | hsa05171 | Coronavirus disease - COVID-19 | 3.15E-04 | 9 | P01584, P62753, P25398, Q9UHA3, P36578, P32969, P18077, P62829, O14786 | IL1B, RPS6, RPS12, RSL24D1, RPL4, RPL9, RPL35A, RPL23, NRP1 | More | | | Lormetazepam | hsa05202 | Transcriptional misregulation in cancer | 9.99E-05 | 16 | Q12778, Q15532, Q13315, P14780, P27930, Q16548, Q13077, Q15652, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P24522 | FOXO1, SS18, ATM, MMP9, IL1R2, BCL2A1, TRAF1, JMJD1C, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, GADD45A | More | | | Lormetazepam | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | | Lormetazepam | hsa05217 | Basal cell carcinoma | 1.43E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | | Lormetazepam | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | | Lormetazepam | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.46E-04 | 10 | P07766, P20963, P09693, P06239, O60603, P10747, Q04759, Q16539, Q9HC35, P01730 | CD3E, CD247, CD3G, LCK, TLR2, CD28, PRKCQ, MAPK14, EML4, CD4 | More | | | Lormetazepam | hsa05321 | Inflammatory bowel disease | 2.80E-06 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P42226, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, STAT6, GATA3 | More | | | Lormetazepam | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | | Lormetazepam | hsa05330 | Allograft rejection | 1.51E-03 | 2 | P48023, P01375 | FASLG, TNF | More | | | Lormetazepam | hsa05332 | Graft-versus-host disease | 3.10E-05 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | | Lormetazepam | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | | Lormetazepam | hsa05415 | Diabetic cardiomyopathy | 1.02E-03 | 8 | P05141, O15239, Q16718, O14521, P13073, Q16539, P49841, Q13557 | SLC25A5, NDUFA1, NDUFA5, SDHD, COX4I1, MAPK14, GSK3B, CAMK2D | More | |
|
